2025
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsPatient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis
Sanacora G, Barnett B, Hu B, Goes F, Mathew S, Murrough J, Reti I, Wilkinson S, Anand A. Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis. Psychiatry Research 2025, 347: 116411. PMID: 40049091, DOI: 10.1016/j.psychres.2025.116411.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyResistant depressionTreatment adherenceResponse to ketamineECT-treated patientsTreatment outcome measuresInfluence treatment adherencePatient-Centered Outcomes Research InstituteAssociated with greater likelihoodKetamine treatmentIV ketamineAdverse eventsEffect of patients' preferencesPreference effectsPatient preferencesRandomized patients to treatmentKetamineRate of adverse eventsTreatment responseGreater likelihoodPatients to treatmentPhase completionTreatment preferencesDepressionCD177, MYBL2, and RRM2 Are Potential Biomarkers for Musculoskeletal Infections.
Agidigbi T, Fram B, Molloy I, Riedel M, Wiznia D, Oh I. CD177, MYBL2, and RRM2 Are Potential Biomarkers for Musculoskeletal Infections. Clinical Orthopaedics And Related Research® 2025 PMID: 39915095, DOI: 10.1097/corr.0000000000003402.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsFracture-related infectionRibonucleotide reductase regulatory subunit M2Peripheral blood mononuclear cell levelsPeripheral blood mononuclear cell concentrationsPeriprosthetic joint infectionMusculoskeletal infectionsMonitoring treatment responseDiabetic foot infectionsTreatment responseReceiver operating characteristicPurulent drainageControl groupSerum levelsSinus tractInflammatory markersBlood samplesFoot infectionsInfection groupDiagnostic accuracyTranscriptomic analysis of peripheral blood mononuclear cellsDiagnosis of musculoskeletal infectionsNormalization of inflammatory markersPeripheral blood mononuclear cells of patientsInflammatory conditionsClinical Effectiveness of Electroconvulsive Therapy for Psychotic vs Nonpsychotic Depression: A Cohort Study.
Kelkar R, Liu G, Goodman M, Al-Hashemi A, Rhee T, Blumberger D, Kaster T. Clinical Effectiveness of Electroconvulsive Therapy for Psychotic vs Nonpsychotic Depression: A Cohort Study. The Journal Of Clinical Psychiatry 2025, 86 PMID: 39898922, DOI: 10.4088/jcp.24m15399.Peer-Reviewed Original ResearchConceptsAdverse cognitive effectsMD-PCognitive effectsElectroconvulsive therapyPsychotic symptomsPsychotic featuresAcute course of ECTClinical Global Impression ImprovementTreatment responseClinical effects of electroconvulsive therapyCourse of ECTEffects of electroconvulsive therapyFactors associated with treatment responseElectroconvulsive therapy treatmentsPatient characteristicsNonpsychotic depressionCognitive Functioning ScaleRate of responseAssociated with responseAcute courseRetrospective cohort studyFunctional scalesDepressionAdult inpatientsSymptomsCharacterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Senna M, Taylor S, Piraccini B, Shapiro J, Somani N, Jedynak J, Ogwu S, Buchanan A, Craiglow B, Ohyama M. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s522. DOI: 10.25251/skin.9.supp.522.Peer-Reviewed Original ResearchSeverity of Alopecia ToolLoss of responseSeverity of Alopecia Tool scoreBaricitinib 4 mgLost responseMaintenance treatmentAlopecia areataLong-term maintenance therapyYears of initial treatmentWeeks of maintenance treatmentBaseline disease characteristicsSevere alopecia areataPhase 3 trialYear of treatmentPost hoc analysisBaricitinib monotherapySevere AAMaintenance therapySALT scoreMaintained responseInitial treatmentBaseline characteristicsAdjunctive therapyTreatment responseCOVID-19 infectionHarnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, Tan D, Tan W, Ang H, Carbone D, Yee M, Shanmugam M, Huang X, Sethi G, Tan T, Lim L, Huang R, Ungefroren H, Giovannetti E, Tang D, Bruno T, Luo P, Andersen M, Qian B, Ishihara J, Radisky D, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper K, Shi T, Merghoub T, Krebs S, Kusumbe A, Davids M, Brown J, Kumar A. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. Journal Of Hematology & Oncology 2025, 18: 6. PMID: 39806516, PMCID: PMC11733683, DOI: 10.1186/s13045-024-01634-6.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTumor microenvironmentCancer progressionTherapeutic resistanceCancer therapyTumor microenvironment componentsTumor microenvironment modulationModulation of epithelial-mesenchymal transitionPromote tumor growthImprove treatment efficacyTumor microenvironment signalsTargeted cancer therapyTarget various componentsTherapeutic challengeTreatment responseTumor growthPromote metastasisTherapeutic strategiesTreatment efficacyEpithelial cellsMesenchymal traitsCancer cellsExtracellular matrix componentsCancerResistance mechanismsPredictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease
Lanctôt K, Tumati S, Vieira D, Bawa K, Andreazza A, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Mintzer J, Herrmann N. Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease. Alzheimer's & Dementia 2025, 20: e095596. PMCID: PMC11712725, DOI: 10.1002/alz.095596.Peer-Reviewed Original ResearchTreatment responseBlood-based biomarkersBlood-based biomarkers of neurodegenerationNPI-aClinical predictorsAlzheimer's diseaseClinical predictors of responsePredictive value of biomarkersTumor necrosis factor-alphaOxidative stressNeurofilament lightAffecting treatment responsePredictors of responseNecrosis factor-alphaBiomarkers of neurodegenerationInterleukin (IL)-6Treatment response predictionMonths end pointAssociated with apathyValue of biomarkersNeuropsychiatric Inventory apathy subscalePresence of anxietyPeripheral inflammation
2024
Considering the interconnected nature of social identities in neuroimaging research
Dhamala E, Ricard J, Uddin L, Galea L, Jacobs E, Yip S, Yeo B, Chakravarty M, Holmes A. Considering the interconnected nature of social identities in neuroimaging research. Nature Neuroscience 2024, 28: 222-233. PMID: 39730766, DOI: 10.1038/s41593-024-01832-y.Peer-Reviewed Original ResearchStudy of psychiatric conditionsComplex human behaviorNeuroimaging researchNeuroimaging studiesPsychiatric conditionsBehavioral expressionStudy of behaviorBrain biologyMental health domainsIllness expressionDiverse intersectional identitiesMental healthSociodemographic factorsTreatment responseLife experiencesIndividual variabilityIntersectional identitiesHuman behaviorSocial identityHealth domainsNature of social identitySymptom burdenNeuroimagingParticipant recruitmentBrainA Psychometric Evaluation of the Parenting Anxious Kids Rating Scale (PAKRS-PR) in a Sample of Families with Clinically Anxious Children
DiFonte M, Sain K, Tolin D. A Psychometric Evaluation of the Parenting Anxious Kids Rating Scale (PAKRS-PR) in a Sample of Families with Clinically Anxious Children. Child Psychiatry & Human Development 2024, 1-10. PMID: 39589720, DOI: 10.1007/s10578-024-01793-0.Peer-Reviewed Original ResearchSessions of cognitive behavioral therapyPsychometric evaluationTreatment-seeking sampleCognitive behavioral therapyAssociated with treatment responseTreatment outcome measuresParent-child dyadsSpecialty outpatient clinicAnxiogenic parentingSample of familiesAnxiety severityBehavioral therapyConvergent validityTotal scalePsychometric propertiesRating ScaleItem levelTotal scoreSubscalesWarmth/supportTreatment responseCronbach's aOutcome measuresParentsAnxietyA Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers
Dhingra L, Sangha V, Aminorroaya A, Bryde R, Gaballa A, Ali A, Mehra N, Krumholz H, Sen S, Kramer C, Martinez M, Desai M, Oikonomou E, Khera R. A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers. The American Journal Of Cardiology 2024, 237: 35-40. PMID: 39581517, PMCID: PMC11761372, DOI: 10.1016/j.amjcard.2024.11.028.Peer-Reviewed Original ResearchCleveland Clinic FoundationHypertrophic cardiomyopathyMedian follow-up periodHypertrophic cardiomyopathy therapyMonitoring treatment responseFollow-up periodImpact of therapyAtlantic Health SystemLack of improvementOral alternativePost-SRTMedical therapyTreatment responseMulticenter evaluationInterventricular septumPercutaneous reductionMavacamtenTherapyPatientsClinic FoundationPoint-of-care monitoringECGECG imagesScoresHealth systemFunctional Connectivity Biomarkers in Schizophrenia
Howell A, Anticevic A. Functional Connectivity Biomarkers in Schizophrenia. Advances In Neurobiology 2024, 40: 237-283. PMID: 39562448, DOI: 10.1007/978-3-031-69491-2_10.Peer-Reviewed Original ResearchConceptsFunctional connectivityResponse to antipsychotic medicationDebilitating neuropsychiatric disorderAbnormal brain functionFood and Drug AdministrationFunctional connectivity biomarkersAntipsychotic medicationNeural alterationsNeural changesPsychiatric conditionsNeuropsychiatric disordersNeural mechanismsBrain regionsSchizophreniaFC biomarkersNational Institutes of HealthConnectivity biomarkersBrain functionMagnetic resonance imaging (MRI)-based studyUS Food and Drug AdministrationFC metricsTreatment responseFDA-approved biomarkersPublic health problemPatient subgroupsSorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsAn Artificial Intelligence-Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma.
Li Q, Zhang W, Liao T, Gao Y, Zhang Y, Jin A, Ma B, Qu N, Zhang H, Zheng X, Li D, Yun X, Zhao J, Yu H, Gao M, Wang Y, Qian B. An Artificial Intelligence-Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma. Clinical Cancer Research 2024, 31: 139-150. PMID: 39535738, DOI: 10.1158/1078-0432.ccr-24-2356.Peer-Reviewed Original ResearchPapillary thyroid carcinomaPapillary thyroid carcinoma patientsDisease-free survivalThyroid carcinomaInflammatory subtypeRadiomics signatureTreatment responseSubtype of papillary thyroid carcinomaTianjin Medical University Cancer Institute and HospitalAssociated with poor disease-free survivalFudan University Shanghai Cancer CenterPoor disease-free survivalCancer Institute and HospitalTreatment response of patientsComplications risk stratificationShanghai Cancer CenterAnti-inflammatory traditional Chinese medicinesResponse of patientsPreoperative ultrasound imagingValidation set 2Clinicopathological variablesTraining set 1Evaluate prognosisPoor prognosisRisk stratificationPlasma NGAL, not IFN-γ, predicts early treatment response in drug-naïve Chinese Han schizophrenia patients
Sun X, Li M, Qiu Y, Su Q, Wang J, Bi F, Li J. Plasma NGAL, not IFN-γ, predicts early treatment response in drug-naïve Chinese Han schizophrenia patients. Schizophrenia Research 2024, 274: 457-463. PMID: 39515255, DOI: 10.1016/j.schres.2024.10.025.Peer-Reviewed Original ResearchDrug-naive schizophrenia patientsSchizophrenia patientsNeutrophil gelatinase-associated lipocalinNeutrophil gelatinase-associated lipocalin concentrationsEarly treatment responseDuration of untreated illnessTreatment responseIFN-gHealthy controlsNGAL concentrationsEarly prediction of treatment efficacyPlasma neutrophil gelatinase-associated lipocalinNeutrophil gelatinase-associated lipocalin levelsUntreated illnessPrediction of treatment efficacyPredicting early treatment responsePlasma NGAL concentrationsWeeks of treatmentIFN-g levelsPersonalized treatment strategiesLogistic regression analysisBaseline NGAL concentrationLongitudinal studySchizophreniaTreatment outcomesA Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML
Mosialou I, Ali A, Cuesta-Dominguez A, Labella R, Vgenopoulou V, Bisikirska B, Galan-Diez M, Wang A, Bewersdorf J, Liang C, Heiblig M, Jurcic J, Berman E, Rabadan R, Kornblau S, Garcia-Manero G, Raza A, Kousteni S. A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML. Blood 2024, 144: 5788-5788. DOI: 10.1182/blood-2024-212307.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute myeloid leukemia patientsStandard of careComplete responseMyelodysplastic syndrome patientsMyelodysplastic syndromeOverall response rateResponse to ATRAAll-trans-retinoic acidB-cateninOsteoblast lineage cellsMyeloid malignanciesTreatment responseLineage cellsDuration of follow-upMonitoring of treatment responseResponse rateBone marrow biopsyAbsolute neutrophil countAdverse risk groupAcute myeloid leukemia cellsNotch signalingAssociated with complete inhibitionResponse to all-trans-retinoic acidResistance to standardRadiation Therapy for the Treatment of Osteoarthritis
Yu J, Grew D, Spraker M, Beckta J, Shah C, Brower J. Radiation Therapy for the Treatment of Osteoarthritis. Practical Radiation Oncology 2024, 15: 19-24. PMID: 39503700, DOI: 10.1016/j.prro.2024.09.003.Peer-Reviewed Original ResearchConceptsRadiation therapyAssessment of treatment responseTreatment of osteoarthritisMedically refractory diseaseNonsteroidal anti-inflammatory drugsNoninvasive treatment optionCause of painCyclooxygenase-2 inhibitorsIntra-articular corticosteroid therapyAnti-inflammatory drugsCorticosteroid therapyRefractory diseaseTreatment responseTreatment optionsClinical evidenceOlder patientsTherapyCyclooxygenase-2PatientsTraditional treatmentPhysical therapyPainTreatmentOsteoarthritisTechnical considerationsEndoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel
Panel T, Shen B, Abreu M, Cohen E, Farraye F, Fischer M, Feuerstadt P, Kapur S, Ko H, Kochhar G, Liu X, Mahadevan U, McBride D, Navaneethan U, Regueiro M, Ritter T, Sharma P, Lichtenstein G. Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. Gastrointestinal Endoscopy 2024, 101: 295-314. PMID: 39425706, DOI: 10.1016/j.gie.2024.08.034.Peer-Reviewed Original ResearchInflammatory bowel diseaseInflammatory bowel disease specialistsAssessment of treatment responseBowel diseaseClinical practice patternsConsensus documentMonitoring of disease activityAdult inflammatory bowel diseaseDysplasia surveillancePractice patternsGI pathologistsEndoscopic aspectDisease activityEndoscopic managementPostoperative evaluationConsensus panelTreatment responseInterventional therapyEndoscopic diagnosisIBD managementDiagnosisDiseaseFOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types
Zhang X, Ma J, Chen Y, Deng X, Zhang Y, Han Y, Tan J, Deng G, Ouyang Y, Zhou Y, Cai C, Zeng S, Shen H. FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types. Molecular Therapy Oncology 2024, 32: 200895. PMID: 39583007, PMCID: PMC11584611, DOI: 10.1016/j.omton.2024.200895.Peer-Reviewed Original ResearchImmunotherapy resistanceB cellsPoor response to immunotherapyExpression of Blimp-1Cancer typesResponse to immunotherapyDifferentiation of B cellsB cell subpopulationsAssociated with poor response to immunotherapyPredicting treatment responseAffecting treatment efficacyDiverse cancer typesImmunotherapy efficacyImmunotherapy patientsTumor microenvironmentTreatment responsePlasma cellsImmunotherapyImmunosuppressive effectsBlimp-1Spatial transcriptomic analysisTreatment efficacyOvercome resistanceCancer treatmentImmunofluorescence analysisMapping extrachromosomal DNA amplifications during cancer progression
Kim H, Kim S, Wade T, Yeo E, Lipsa A, Golebiewska A, Johnson K, An S, Ko J, Nam Y, Lee H, Kang S, Chung H, Niclou S, Moon H, Paek S, Bafna V, Luebeck J, Verhaak R. Mapping extrachromosomal DNA amplifications during cancer progression. Nature Genetics 2024, 56: 2447-2454. PMID: 39402156, PMCID: PMC11549044, DOI: 10.1038/s41588-024-01949-7.Peer-Reviewed Original ResearchConceptsPretreatment tumorsCancer progressionChemotherapy-pretreated patientsNewly diagnosed tumorsVariant allele fractionUntreated metastasesPrimary cancerUntreated cancerTreatment responseFocal amplificationTumor samplesChromosomal amplificationsDiagnosed cancerTumorExtrachromosomal DNA amplificationsAdvanced cancerCancerEcDNATime pointsMetastasisNewlyDNA amplificationProgressionExtrachromosomal DNAPatientsTuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.Commentaries, Editorials and Letters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply